Cogent Biosciences: Bezuclastinib’s Strong Phase 3 Data and Multiple 2026 NDA Filings Underpin Reiterated Buy and $52 Target

Cogent Biosciences, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Robert Burns from H.C. Wainwright reiterated a Buy rating on the stock and has a $52.00 price target.

Robert Burns has given his Buy rating due to a combination of factors tied primarily to the clinical and regulatory progress of bezuclastinib. He highlights that by mid-2026 Cogent plans to have three New Drug Applications for bezuclastinib under FDA review, covering non-advanced systemic mastocytosis, advanced systemic mastocytosis, and second-line gastrointestinal stromal tumors (GIST). In second-line GIST, the combination of bezuclastinib with Sutent produced materially better response and progression-free survival outcomes than Sutent alone in the Phase 3 PEAK trial, suggesting this regimen could become the preferred standard of care and a high commercial-value indication. Burns also notes that the efficacy benchmark set by bezuclastinib appears competitive relative to emerging rivals such as GSK6042981, reinforcing the drug’s differentiated profile.
In advanced systemic mastocytosis, the Phase 3 APEX trial showed strong overall response rates and marked reductions in disease biomarkers, indicating robust activity against KIT-driven disease and supporting the case for regulatory approval. Burns views these data as sufficiently strong that he anticipates a relatively smooth FDA review across the targeted indications, reducing regulatory risk. Additionally, he underscores management’s intention to broaden bezuclastinib’s use through multiple ongoing and planned studies, which could expand the addressable market over time. Taken together, these factors underpin his confidence in Cogent’s value creation potential and support his reiterated Buy rating and $52 12‑month price target.

In another report released yesterday, Wedbush also maintained a Buy rating on the stock with a $55.00 price target.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of COGT in relation to earlier this year.